Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

Brain injury after spontaneous intracerebral hemorrhage results from pathophysiologic responses in the brain parenchyma due to hematoma formation, release of clot components, and surrounding edema. Inflammatory cascade activation in the perihematomal brain parenchyma has been implicated in the pathogenesis of secondary brain injury. Statins have been identified as a potential neuroprotective agent that targets the inflammatory response to intracerebral hemorrhage. In preclinical studies, statin treatment in animal intracerebral hemorrhage models has consistently demonstrated neuroprotective and recovery enhancement effects. Clinical investigations in humans reported better patient outcomes associated with statin use in patients with intracerebral hemorrhage, including reduced perihematomal edema, lower mortality rates, and improved functional outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age of 18 years or older

• A clinical diagnosis of supratentorial intracerebral hemorrhage is confirmed by brain CT scan

• Hematoma volume ≤40ml

• The first dose of statin can be given within 24h of intracerebral hemorrhage symptom onset (if the patient is randomized to statin group)

• Written informed consent

Locations
Other Locations
China
Hebei Province Shunping County Hospital
RECRUITING
Baoding
Beijing Fengtai Youanmen Hospital
RECRUITING
Beijing
Xuan Wu Hospital,Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Chuanjie Wu, Dr.
wuchuanjie8557@163.com
18911366882
Time Frame
Start Date: 2021-08-06
Estimated Completion Date: 2024-11-30
Participants
Target number of participants: 98
Treatments
Experimental: Statins group
No_intervention: Control group
Sponsors
Leads: Capital Medical University

This content was sourced from clinicaltrials.gov